Qianjin Pharmaceutical released its 2026 interim report. First-half net profit attributable to the parent company was 181 million yuan, up 41.6% year on year. Operating revenue was 1.92 billion yuan, up 5.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 176 million yuan, up 49.4% year on year. Net operating cash flow was 53.07 million yuan, up 219.3% year on year. Second-quarter operating revenue was 948 million yuan, up 16.6% year on year, and net profit attributable to the parent was 106 million yuan, up 41.9% year on year. The company focuses on the research, production and sale of Chinese patent medicines, chemical drugs and feminine hygiene products, and invested in 117 research projects during the reporting period.
ZhuZhou QianJin Pharmaceutical Co LtdFirst-half net profit up 41.6% year on year, with strong cash flow growth.
